A股收評：三大股指均收跌，題材板塊多數走弱，疫苗、豬肉股領跌
9月16日，A股三大指數均走弱收跌，截至收盤，滬指報3283.92點，跌0.36%，深證成指報13011.28點，收跌1.01%，創業板報2554.80點，收跌1.55%。北向資金淨流入7.42億。
圖片來源：wind
兩市成交量繼續縮量，不足7000億，值得一提的是創業板綜指縮量，次新股卡倍億連續4日漲停。軍工、豬肉、食品、疫苗等板塊跌幅居前，兩市個股跌多漲少，漲停僅30餘家，市場賺錢效應較差。
具體來看：
創業板次新股繼續炒作，卡倍億連續4日漲停，大葉股份、迦南智能、歐陸通、藍盾光電漲停，其餘個股紛紛大漲。
國家發改委新聞發言人表示，下一步，我們將深入貫徹落實新《證券法》要求，深入推進企業債券註冊制改革，加強信息披露和事中事後監管，推動企業債券更好服務實體經濟
圖片來源：同花順
汽車整車延續強勢，長城汽車、ST海馬、長安汽車、比亞迪漲幅均超4%，宇通客車、長安B、廣汽集團等個股紛紛跟漲。
惠譽評級預計，2020年中國汽車經銷商盈利能力和槓桿率的惡化將是暫時的，業務復甦將持續到2021年。
圖片來源：富途
儲能概念走強，龍頭股陽光電源再度大漲超6%，國軒高科、比亞迪等個股紛紛跟漲。
華安證券：“十四五”規劃中2030年非化石能源佔比，預期未來新能源裝機將有較大增長，導致光伏和風電板塊均有一定程度上的上漲。長期來看新能源發電佔比提升的確定性極高，短期風電光伏企業的業績均保持高增長。在業績和政策的雙驅動下，板塊熱度有望持續，行業有望迎來二次上漲。
圖片來源：富途
生物疫苗繼續調整，長春高新、康華生物、東寶生物跌幅超5%，復星醫藥、賽升藥業、未名醫藥跌幅超4%。
中金報告指出：新冠疫苗年內落地是大概率事件。保守估計2020年4季度出現疫苗宣佈臨牀試驗成功的概率超95%，偏樂觀估計11月和12月單月出現疫苗宣佈臨牀試驗成功的概率皆超98%。
圖片來源：富途
豬肉股再度重挫，權重股牧原股份大跌4.14%，天康生物、湘佳生物、上海梅林等個股紛紛跟跌。
國家發改委：菜價有望短時間回落，確保兩節期間豬肉價格平穩
圖片來源：富途
資金流向方面，房地產、銀行、電工電網均淨流入超6個億；製藥、酒類、軟件、生物科技等行業淨流出超10個億。
圖片來源：wind
科創板方面，光雲科技、固德威、龍騰光電漲幅居前，均超9%；瑞晟智能、綠的諧波、安恆信息、傳音控股、新光光電等個股跌超4%。
圖片來源：wind
北向資金方面，全天淨流入7.42億元，滬股通淨流入22.28億元，深股通淨流出14.86億元。
圖片來源：東方財富
中原證券指出：近日兩市持續縮量，後市再度面臨突破方向的選擇，建議投資者密切關注政策面，資金面以及外部因素的變化情況，謹慎關注低估值藍籌股的投資機會。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
